Management of hyponatremia: Providing treatment and avoiding harm

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 10, 2010, Pages 715-726

  Vaidya, Chirag ^a   Ho, Warren ^b   Freda, Benjamin J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Franklin Square Hospital Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; SODIUM; SODIUM CHLORIDE; VASOPRESSIN RECEPTOR;

BRAIN EDEMA; DEMYELINATING DISEASE; DRUG ANTAGONISM; EXTRACELLULAR FLUID; FIBROSIS; FLUID THERAPY; HUMAN; HYPONATREMIA; OSMOLARITY; PRACTICE GUIDELINE; REVIEW; SCHWARTZ BARTTER SYNDROME;

BRAIN EDEMA; DEMYELINATING DISEASES; DIURETICS; EXTRACELLULAR FLUID; FIBROSIS; FLUID THERAPY; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; OSMOLAR CONCENTRATION; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, VASOPRESSIN; SALINE SOLUTION, HYPERTONIC; SODIUM;

EID: 77958020674     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.08051     Document Type: Review

References (33)

1. Flear CTG, Gill GV, Burn J. Hyponatremia: mechanisms and management. Lancet 1981; 2:26-31.
2. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120(suppl 1):S1-S21.
3. Freda BJ, Davidson MB, Hall PM. Evaluation of hyponatremia: a little physiology goes a long way. Cleve Clin J Med 2004; 71:639-650.
4. Weisberg LS. Pseudohyponatremia: a reappraisal. Am J Med 1989; 86:315-318.
5. Moritz L, Ayus JC. The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant 2003; 18:2486-2491.
6. Widdess-Walsh P, Sabharwal V, Demirjian S, DeGeorgia M. Neurologic effects of hyponatremia and its treatment. Cleve Clin J Med 2007; 74:377-383.
7. Melton JE, Patlak CS, Pettigrew KD, Cserr HF. Volume regulatory loss of Na, Cl, and K from rat brain during acute hyponatremia. Am J Physiol 1987; 252:F661-F669.
8. Lauriat SM, Berl T. The hyponatremic patient: practical focus on therapy. J Am Soc Nephrol 1997; 8:1599-1607.
9. Kokko JP. Symptomatic hyponatremia with hypoxia is a medical emergency. Kidney Int 2006; 69:1291-1293.
10. Ellis SJ. Severe hyponatraemia: complications and treatment. QJM 1995; 88:905-909.
11. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4:1522-1530.
12. Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008; 3:331-336.
13. Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int 2009; 76:587-589.
14. Nguyen MK, Kurtz I. Analysis of current formulas used for treatment of the dysnatremias. Clin Exp Nephrol 2004; 8:12-16.
15. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342:1581-1589.
16. Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2007; 2:1110-1117.
17. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356:2064-2072.
18. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119:71.e1-e8.
19. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010; 5:275-280.
20. Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med 1987; 83:905-988.
21. Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM 2005; 98:529-540.
22. Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 2008; 19:1076-1078.
23. Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J. Renal failure associated with demeclocycline in cirrhosis. Ann Intern Med 1977; 87:195-197.
24. Lehrich RW, Greenberg A. When is it appropriate to use vasopressin receptor antagonists? J Am Soc Nephrol 2008; 19:1054-1058.
25. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008; 371:1624-1632.
26. Schrier RW, Gross P, Gheorghiade M, et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099-2112.
27. Konstam MA, Gheorghiade M, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319-1331.
28. Berl T, Quittnat-Pelletier F, Verbalis JG, et al; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705-712.
29. Greenberg A, Lehrich RW. Treatment of chronic hyponatremia: now we know how, but do we know when or if? J Am Soc Nephrol 2010; 21:552-555.
30. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69:2124-2130.
31. Rosner MH, Kirven J. Exercise-associated hyponatremia. Clin J Am Soc Nephrol 2007; 2:151-161.
32. Halperin ML, Kamel KS, Sterns R. Hyponatremia in marathon runners. N Engl J Med 2005; 353:427-428.
33. Hew-Butler T, Almond C, Ayus JC, et al; Exercise-Associated Hyponatremia (EAH) Consensus Panel. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa 2005. Clin J Sport Med 2005; 15:208-213.